These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 10478702)

  • 21. Benefits of combination therapy in hypertensive patients with associated coronary artery disease: a subgroup with specific demands.
    Morisco C; Lembo G; Sarno D; Argenziano L; Fratta L; Rozza F; Trimarco B
    J Cardiovasc Pharmacol; 1998; 31 Suppl 2():S27-33. PubMed ID: 9605599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Managing hypertension using combination therapy.
    Frank J
    Am Fam Physician; 2008 May; 77(9):1279-86. PubMed ID: 18540493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination antihypertensive therapy in the treatment of diabetic nephropathy.
    Boner G; Cao Z; Cooper ME
    Diabetes Technol Ther; 2002; 4(3):313-21. PubMed ID: 12165170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of combined Angiotensin-converting enzyme inhibition and calcium antagonism on allograft coronary vasculopathy validated by intravascular ultrasound.
    Erinc K; Yamani MH; Starling RC; Crowe T; Hobbs R; Bott-Silverman C; Rincon G; Young JB; Feng J; Cook DJ; Smedira N; Tuzcu EM
    J Heart Lung Transplant; 2005 Aug; 24(8):1033-8. PubMed ID: 16102438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of the fixed-dose combination lercanidipine-enalapril in renal protection.
    Egan CG; Pontremoli R
    J Nephrol; 2011; 24(4):428-37. PubMed ID: 21279953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies.
    Schmieder RE; Martus P; Klingbeil A
    JAMA; 1996 May; 275(19):1507-13. PubMed ID: 8622227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiac benefits of ACE inhibitors and calcium antagonists alone and in combination.
    Sleight P
    J Cardiovasc Pharmacol; 1994; 23 Suppl 1():S39-42. PubMed ID: 7519696
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between cardiovascular outcomes and antihypertensive drug treatment in older women.
    Wassertheil-Smoller S; Psaty B; Greenland P; Oberman A; Kotchen T; Mouton C; Black H; Aragaki A; Trevisan M
    JAMA; 2004 Dec; 292(23):2849-59. PubMed ID: 15598916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal protection and antihypertensive drugs: current status.
    Salvetti A; Mattei P; Sudano I
    Drugs; 1999 May; 57(5):665-93. PubMed ID: 10353294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Optimization of the control of blood pressure. What contribution can be obtained from use of combinations of fixed doses of ace inhibitors and calcium channel blockers?].
    Eliseev OM
    Ter Arkh; 2011; 83(5):70-5. PubMed ID: 21780662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Combination therapy in primary hypertension].
    Halawa B
    Pol Merkur Lekarski; 1998 Jan; 4(19):35-8. PubMed ID: 9553408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiac effects of combination therapy.
    Messerli FH; Michalewicz L
    Am J Hypertens; 1997 Jul; 10(7 Pt 2):146S-152S. PubMed ID: 9231891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fixed low-dose combination of an angiotensin converting enzyme inhibitor and a calcium channel blocker drug in the treatment of essential hypertension.
    de Leeuw PW; Kroon AA
    J Hypertens Suppl; 1997 Mar; 15(2):S39-42. PubMed ID: 9218197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RAS inhibition in hypertension.
    Ibrahim MM
    J Hum Hypertens; 2006 Feb; 20(2):101-8. PubMed ID: 16397519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial.
    Düsing R; Sellers F
    Curr Med Res Opin; 2009 Sep; 25(9):2287-301. PubMed ID: 19635044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of combination therapy on the heart.
    Messerli FH; Michalewicz L
    J Hum Hypertens; 1997 Jan; 11(1):29-33. PubMed ID: 9111154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MORE--MOexipril and REgression of left ventricle hypertrophy in combination therapy A multicentric open label clinical trial.
    Spinar J; Vítovec J;
    Int J Cardiol; 2005 Apr; 100(2):199-206. PubMed ID: 15823625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ?
    Bakris GL; Williams B
    J Hypertens Suppl; 1995 Aug; 13(2):S95-101. PubMed ID: 8576797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Medical treatment of hypertension--what treatment for what patients?].
    Zidek W; Tepel M; van der Giet M
    MMW Fortschr Med; 2004 May; 146(22):31-4. PubMed ID: 15373106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.